Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF). Conclusion In not hospitalized patients with HFREF of ischemic etiology, obesity was not a protective factor.

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

HeartRhythm

SEPTEMBER 4, 2024

Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Quality of Life 40

Circulation: Heart Failure

JANUARY 26, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pharmacology Obesity Circulation 40

Journal of the American Heart Association

DECEMBER 29, 2023

AF increases the risk of stroke, heart failure, dementia, and hospitalization. Obesity significantly increases AF risk, both directly and indirectly, through related conditions, like hypertension, diabetes, and heart failure. ABSTRACTAtrial fibrillation (AF) is the most common cardiac arrhythmia.

Obesity 45

Obesity Atrial Fibrillation Heart Failure Dementia 45

Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Journal of Cardiovascular Pharmacology

JUNE 24, 2024

Sodium/glucose cotransporter 2 (SGLT2) inhibitors are a novel class of anti-diabetic medications which have proved capable of providing breakthrough cardiovascular benefits in a variety of clinical scenarios, including patients with heart failure or obesity, irrespective of diabetic status.

Myocardial Infarction 40

Myocardial Infarction Heart Failure Pharmacology Diabetes 40

Frontiers in Cardiovascular Medicine

FEBRUARY 4, 2024

Notably, MAM exhibits various regulatory effects to maintain cellular balance in several cardiac diseases conditions, such as obesity, diabetes mellitus, and cardiotoxicity. Cardiac diseases caused by any reason can lead to changes in myocardial structure and function, significantly impacting human health.

Pharmacology 69

Pharmacology Obesity Heart Failure Diabetes 69